Jeff E. Knight - Mar 22, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Operating Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Mar 22, 2024
Transactions value $
-$714,275
Form type
4
Date filed
3/26/2024, 04:30 PM
Previous filing
Mar 20, 2024
Next filing
Jun 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $719K +30K +54.61% $23.98 84.9K Mar 22, 2024 Direct
transaction CRNX Common Stock Sale -$1.33M -30K -35.32% $44.22 54.9K Mar 22, 2024 Direct F1
transaction CRNX Common Stock Sale -$107K -2.36K -4.29% $45.39 52.6K Mar 22, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Options Exercise $0 -30K -18.75% $0.00 130K Mar 22, 2024 Common Stock 30K $23.98 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.22 per share. The range of sales prices on the transaction date was $44.00 to $44.52 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.